The Launching of the First Unprecedented Study in Syria (SIRAS) in Ramadan

Wednesday, August 1, 2012

Under the slogan of Ibn Al haytham Pharmaceutical Industries (Partners in Health), the company promotes partnership with doctors in the field of Health & patients public interest in addition to Health awareness . For the purpose of society service and the enhancement of scientific research in Syria, Ibn Al Haytham Pharmaceutical Industries is working on an observational study for patients with type 2 diabetes in Syria through a survey on Sitacretin Plus product which is consisted of (Sitagliptin + Metformin).

The primary endpoint of this Study is counting the number of hypoglycemic episodes that are frequently increased in Ramadan in Muslim patients with type 2 diabetes. It is based on a comparison between two groups; one group will be treated by Sitacretin Plus and the other group to be treated with sulphonylurea + Metformin. A number of specialists from Aleppo & Damascus will supervise this study in which each patient will have a finger stick glucometer and a free checking on HbA1c in an authoritative center.

The name of this study is (SIRAS Trial) - an Observational Study on the incidence of hypoglycemia in Muslim patients with type 2 diabetes treated with Sitagliptin + Metformin or a sulphonylurea + Metformin during Ramadan in Syria - .

It’s worth mentioning that this study is the third one presented by Ibn Al Haytham Pharma after two prosperous studies on Antihypertensive products ( REST Study on Revosyl & VHEST Study on Valsartan ) in which they included more than 3000 hypertensive patients in Syria .